(Q33406299)

English

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors (English)

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

Andreas Hochhaus

6

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

Jorge Eduardo Cortes

object named as

J Cortes

1

1 reference

ORCID Public Data File 2021

author name string

R Digumarti

2

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

P M Parikh

3

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

M Wetzler

4

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

J H Lipton

5

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

A R Craig

7

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

A-C Benichou

8

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

F E Nicolini

9

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

H M Kantarjian

10

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

Omacetaxine 203 Study Group

11

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

publication date

7 March 2013

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

American Journal of Hematology

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

88

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

5

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

350-354

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558840

21 June 2018

The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558840

21 June 2018

Challenges for allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia in the era of tyrosine kinase inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558840

21 June 2018

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558840

21 June 2018

The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558840

21 June 2018

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558840

21 June 2018

The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558840

21 June 2018

U2504 Determines the Species Specificity of the A-Site Cleft Antibiotics:

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558840

21 June 2018

Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558840

21 June 2018

Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558840

21 June 2018

A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558840

21 June 2018

Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558840

21 June 2018

Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558840

21 June 2018

Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5558840

21 June 2018

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23408

21 January 2018

Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23408

21 January 2018

Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23408

21 January 2018

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response o

1 reference

https://api.crossref.org/works/10.1002%2FAJH.23408

21 January 2018

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23468307

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/23468307

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/AJH.23408

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

release_xxkbjpyii5euvfke77ts3obyve

1 reference

https://api.fatcat.wiki/v0/release/xxkbjpyii5euvfke77ts3obyve

24 November 2022

based on heuristic

mapped directly with Wikidata item

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

30 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33406299&oldid=1956194987"